Why the Starpharma (ASX:SPL) share price raced higher today

The biopharmaceutical company's shares are continuing their positive run this week…

| More on:
a group of doctors and medical staff in uniform high five in celebration in a hospital setting

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Starpharma Holdings Limited (ASX: SPL) share price finished in the green today following a positive release by the company.

At Tuesday's market close, the biopharmaceutical company's shares were up 3.46% to $1.345.

What did Starpharma announce?

Starpharma announced the results for its multiple dose clinical safety study for its Viraleze antiviral nasal spray.

The company said the product was very well tolerated, with no notable or serious adverse events reported.

Starpharma also confirmed the antiviral agent in Viraleze, SPL7013, was not absorbed into the bloodstream following repeated nasal application. This is in line with previous non-clinical and clinical data.

The randomised, double-blind study involved 40 healthy volunteers who used Viraleze four times a day for a 2-week period. The primary objective of the trial was to assess the safety and tolerability of Viraleze.

Starpharma CEO Dr Jackie Fairley commented:

We are pleased to report that Viraleze was very well tolerated in the study. This additional clinical data adds to the extensive body of evidence for SPL7013, demonstrating its extremely benign safety profile and confirming lack of systemic absorption of SPL7013 in Viraleze. These data further support the suitability of Viraleze antiviral nasal spray for use in everyday situations as a preventative product where individuals may be at risk of exposure to respiratory viruses.

An antiviral nasal spray like Viraleze is advantageous because respiratory viruses, including SARS-CoV-2, take hold by initially infecting mucosal cells in the nasal cavity, and Viraleze and SPL7013 form a barrier that traps and irreversibly inactivates viruses before they can infect cells.

Quick take on Viraleze

Viraleze is an antiviral nasal spray that has shown in laboratory studies to inactivate a broad spectrum of respiratory/cold viruses. This includes multiple variants of SARS-CoV-2 (COVID-19), influenza, RSV, SARS, and MERS (Middle East Respiratory Syndrome).

Starpharma's Viraleze is currently registered for sale in Europe and India. It is not approved for sale or supply in Australia.

About the Starpharma share price

Over the last 12 months, Starpharma shares gained 27%, but tracked the other way in 2021, down 13%.

Starpharma presides a market capitalisation of roughly $548.2 million, with approximately 406 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

An oil worker assesses productivity at an oil rig as ASX 200 energy shares continue to rise.
Share Market News

ASX 200 energy shares lead for the second week as world awaits US decision on Iran

ASX energy shares lifted 5.31% while the ASX 200 fell 0.49% amid the US President contemplating strikes.

Read more »

Two brokers analysing stocks.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A young well-dressed couple at a luxury resort celebrate successful life choices.
Broker Notes

These ASX 200 shares could rise 40% to 50%

Analysts at Macquarie see potential for these shares to deliver the goods for investors.

Read more »

A young man wearing glasses writes down his stock picks in his living room.
Opinions

2 amazing ASX shares I wish I'd bought earlier

I think these stocks are performing incredibly well.

Read more »

Person handing out $100 notes, symbolising ex-dividend date.
Share Market News

$20,000 invested in CBA and these ASX 200 shares 5 years ago is worth

Did these shares deliver the goods for investors? Let's find out.

Read more »

a business person checks his mobile phone outside a Wall Street office with an American flag and other business people in the background.
Share Market News

Is the 'sell America' trade back?

Institutional investors appear to be at odds with retail investors.

Read more »

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to a disappointing week for investors this Friday.

Read more »

Six smiling office colleagues stand in a row and look at the camera.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »